| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/02/2003 | US20030004132 Binding to galectins; therapy for autoimmune disease |
| 01/02/2003 | US20030004113 Autoimmune disease; rheumatic disorders |
| 01/02/2003 | US20030004106 Interleukin-1 receptor antagonist-related molecules and uses thereof |
| 01/02/2003 | US20030004091 Medicinal combination useful for in vivo exogenic transfection and expression |
| 01/02/2003 | US20030003532 Novel nucleic acid sequences encoding human slit-, megf-, and roundabout-like polypeptides |
| 01/02/2003 | US20030003516 Therapeutic and diagnostic uses of antibody specificity profiles |
| 01/02/2003 | US20030003511 Closure of bacterial ghost |
| 01/02/2003 | US20030003502 Three-dimensional model of a complex between a Fc epsilon receptor alpha chain and a Fc region of an IgE antibody and uses thereof |
| 01/02/2003 | US20030003462 Novel human interleukin-like proteins and polynucleotides encoding them |
| 01/02/2003 | US20030003169 Prepared by fermenting an aqueous Glycine max (L.) extract with at least one lactic acid bacteria together with at least one yeast |
| 01/02/2003 | US20030003150 System for osmotic delivery of pharmaceutically active agents |
| 01/02/2003 | US20030003133 Use of milk and milk- related products as a carrier or delivery vehicle for allergens in the process of oral tolerance induction and prevent allergic conditions |
| 01/02/2003 | US20030003132 A mucosal immunoregulatory agent using trehalose as an effective ingredient, which is prepared into foods, beverages and feeds including pet foods |
| 01/02/2003 | US20030003121 Antiallergic agent |
| 01/02/2003 | US20030003120 A phenolic fraction of fruit obtained from the Rosaceae family, including at least 10% by weight of the sum of phloridzin, chlorogenic acid, epicatechin, quercitrin, procyanidin B2, p-coumaric acid and caffeic acid |
| 01/02/2003 | US20030003110 Immunomodulatory effective compositions, methods for the production thereof and their use |
| 01/02/2003 | US20030003106 Use of protein derived from cancer cells, cells infected by a virus or immune cells or an inactive fragment thereof, protein being initially an immunosuppressive and/or angiogenic protein for obtaining medicines to provide mucosal immunity |
| 01/02/2003 | US20030003099 Immunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejection |
| 01/02/2003 | US20030003097 Recombinant antibodies coexpressed with GnTIII |
| 01/02/2003 | US20030003092 Administering an immunotherapeautic agent in conjunction with a tumour growth restricting agent, in amounts effective to eradicate any advanced or large tumours present |
| 01/02/2003 | US20030003085 Drug delivery of a muscle protein by administering purified donor muscle side population cells; gene therapy, in the treatment muscle diseases muscular dystrophies, genetic diseases, treating cancer, and bone marrow transplant |
| 01/02/2003 | US20030003082 Use of poly-Glu,Tyr and T cells treated therewith for neuroprotective therapy |
| 01/02/2003 | US20030003077 A genetic engineered adenoviral vector contains an adenoviral genome from which the open reading frames E1 and/or E3 were deleted and a therapeutic gene or a DNA sequence that encodes for therapeutic proteins useful in fibrosis treatment |
| 01/02/2003 | US20030003051 Methods of achieving transplantation tolerance through radioablation of hemolymphopoietic cell populations |
| 01/02/2003 | US20030000518 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 01/02/2003 | EP1270732A1 Improved transfection of eukaryontic cells with linear polynucleotides by electroporation |
| 01/02/2003 | EP1270595A1 Gene recombinant antibody and its fragment |
| 01/02/2003 | EP1270585A1 Peptide derivative |
| 01/02/2003 | EP1270577A1 Furoisoquinoline derivatives, process for producing the same and use thereof |
| 01/02/2003 | EP1270572A1 Condensed pyrazole derivatives, process for producing the same and use thereof |
| 01/02/2003 | EP1270570A1 Amide compounds and use thereof |
| 01/02/2003 | EP1269198A2 Identification of mast/basophil activation inhibitors |
| 01/02/2003 | EP1269196A1 Method of screening for inhibitors of osteopontin |
| 01/02/2003 | EP1269183A1 Assay for agents that induce chemokinesis |
| 01/02/2003 | EP1268839A1 Beta-glucans from filamentous fungi |
| 01/02/2003 | EP1268802A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 01/02/2003 | EP1268800A2 Mucin-1 specific binding members and methods of use thereof |
| 01/02/2003 | EP1268799A2 Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability |
| 01/02/2003 | EP1268792A2 Wnt-7b-like polypeptides and nucleic acids encoding same |
| 01/02/2003 | EP1268787A2 Human tap-like protein (transporter associated in antigen processing/presentation) |
| 01/02/2003 | EP1268784A2 Genes involved in intestinal inflammatory diseases and use thereof |
| 01/02/2003 | EP1268781A2 G12l, a gene associated with the thermal response |
| 01/02/2003 | EP1268773A1 Immune system-related polynucleotides, polypeptides, and antibodies |
| 01/02/2003 | EP1268764A2 Method for obtaining nucleic acids from an environment sample |
| 01/02/2003 | EP1268759A2 Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
| 01/02/2003 | EP1268753A2 Human protein tyrosine phosphatase, encoding dna and uses thereof |
| 01/02/2003 | EP1268746A2 PRODUCTION OF TcR GAMMA DELTA T CELLS |
| 01/02/2003 | EP1268554A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 01/02/2003 | EP1268553A1 Use of cd25 binding molecules in the treatment of inflammatory diseases of the gastro-intestinal tract |
| 01/02/2003 | EP1268543A2 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 01/02/2003 | EP1268529A2 Immuno-reactive peptide ctl epitopes of human cytomegalovirus |
| 01/02/2003 | EP1268510A2 Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides |
| 01/02/2003 | EP1268504A1 Nucleoside compounds and uses thereof |
| 01/02/2003 | EP1268487A1 Tricyclic protein kinase inhibitors |
| 01/02/2003 | EP1268484A1 Condensed imidazoles as histamine h3 receptor ligands |
| 01/02/2003 | EP1268483A1 Condensed imidazoles as histamine h3 receptor ligands |
| 01/02/2003 | EP1268481A2 Kinase inhibitors as therapeutic agents |
| 01/02/2003 | EP1268474A2 Substituted 1,3-thiazole compounds, their production and use |
| 01/02/2003 | EP1268471A1 N-heterocyclic derivatives as nos inhibitors |
| 01/02/2003 | EP1268455A2 Piperazine derivatives |
| 01/02/2003 | EP1268453A1 Estrogen agonist/antagonist metabolites |
| 01/02/2003 | EP1268445A1 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases |
| 01/02/2003 | EP1268444A1 2,4-di(hetero-)arylamino(-oxy)-5-substituted pyrmidines as antineoplastic agents |
| 01/02/2003 | EP1268437A1 Inhibitors of protein kinases |
| 01/02/2003 | EP1268431A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| 01/02/2003 | EP1268430A1 Chemical complex compprising a pyridine carboxy derivative and an h2 histamine receptor antagonist |
| 01/02/2003 | EP1268425A2 Carbamate caspase inhibitors and uses thereof |
| 01/02/2003 | EP1268419A1 Pyrrolidine derivatives useful as bax inhibitors |
| 01/02/2003 | EP1268418A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors |
| 01/02/2003 | EP1268407A1 Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same |
| 01/02/2003 | EP1268305A1 Infusion packet with useful and decorative elements, support member, delivery system and method |
| 01/02/2003 | EP1268096A1 Extrusion die |
| 01/02/2003 | EP1267945A2 Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor |
| 01/02/2003 | EP1267931A1 Rhodamine derivatives for photodynamic diagnosis and treatment |
| 01/02/2003 | EP1267924A2 Immunotherapeutic methods and compositions |
| 01/02/2003 | EP1267923A1 Use of aliphatic quaternary ammonium as adjuvant in a pharmaceutical composition administered by mucosal delivery |
| 01/02/2003 | EP1267921A1 Composition and method for the prevention and/or the treatment of allergy |
| 01/02/2003 | EP1267918A1 Method of treatment using ligand-immunogen conjugates |
| 01/02/2003 | EP1267915A2 Methods of treating diseases with activated protein c |
| 01/02/2003 | EP1267909A1 Methods of blocking tissue destruction by autoreactive t cells |
| 01/02/2003 | EP1267907A1 Use of mia in immunotherapy |
| 01/02/2003 | EP1267905A2 Composition for the treatment of heart failure |
| 01/02/2003 | EP1267899A2 Salmonella vaccine materials and methods |
| 01/02/2003 | EP1267893A2 Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections |
| 01/02/2003 | EP1267886A2 Vitamin d compounds used to stabilize kidney transplants |
| 01/02/2003 | EP1267876A1 Thrombin inhibitors |
| 01/02/2003 | EP1267870A2 Inhibition of cytokine generation |
| 01/02/2003 | EP1267837A1 Matrices containing nitric oxide donors and reducing agents and their use |
| 01/02/2003 | EP1267834A1 Cationic liposomes |
| 01/02/2003 | EP1267828A2 Pharmaceutical preparations |
| 01/02/2003 | EP1267626A1 Recombinant parainfluenza virus expression systems and vaccines |
| 01/02/2003 | EP1222179A4 Process for preparing piperazine-substituted aliphatic carboxylates |
| 01/02/2003 | EP0999853B1 Stabilized antibody formulation |
| 01/02/2003 | EP0980383B1 Pharmaceutically acceptable salts of 3-hydroxy-estr-5(10)-en-17-one 3-sulphate active as estrogens |
| 01/02/2003 | EP0979284B1 Reagents for vaccination which generate a cd8 t cell immune response |
| 01/02/2003 | EP0930896B1 Method for tolerizing a mammalian patient to administration of gene therapy virus vectors |
| 01/02/2003 | EP0885244B1 Peptide immunogens for vaccination against and treatment of allergy |
| 01/02/2003 | EP0883401B1 At1 receptor antagonist for the stimulation of apoptosis |
| 01/02/2003 | EP0723440B1 Therapeutic delivery compositions and methods of use thereof |
| 01/02/2003 | EP0705245B1 Novel intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives |